Mylan got an approval from the Food and Drug Administration on the generic-drug maker's version of Eliquis.
Eliquis is a tablet for reducing stroke risks and pulmonary embolisms in individuals. The generic, apixaban, is for patients with nonvalvular atrial fibrillation and those who have undergone hip or knee replacement surgery. It’s also used against deep vein thrombosis.
The approval is part of FDA’s program Drug Competition Action Plan, which is aimed at providing more affordable medicine for patients.